Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Treatment Approaches in Newly Diagnosed Multiple Myeloma

July 17th 2015

FDA Approval Sought for Ixazomib in Relapsed/Refractory Myeloma

July 14th 2015

A new drug application has been submitted for the oral proteasome inhibitor ixazomib in combination with lenalidomide and dexamethasone as a treatment for patients with relapsed and/or refractory multiple myeloma

Long-Term Data Further Define Benefit of Lenalidomide Maintenance in Myeloma

July 7th 2015

Philip McCarthy, MD, explains the significance of the updated CALGB 100104 study results.

Novel Antibodies Poised to Transform Myeloma Treatment

July 1st 2015

The landscape of therapeutic options for patients with myeloma at all phases of treatment has rapidly changed with the development of new drugs and targets.

Emerging Concepts in Multiple Myeloma

June 29th 2015

Diagnostic and Response Criteria in Multiple Myeloma

June 29th 2015

ENDEAVOR and CHAMPION Trials in Multiple Myeloma

June 29th 2015

Second-Generation Agents in Relapsed Multiple Myeloma

June 29th 2015

Triplet Therapy in Multiple Myeloma

June 29th 2015

HDAC Inhibitors in Multiple Myeloma

June 29th 2015

Treating Relapsed and Refractory Multiple Myeloma

June 29th 2015

Continuous Therapy in Multiple Myeloma

June 29th 2015

Maintenance Therapy in Multiple Myeloma

June 29th 2015

Defining High-Risk Multiple Myeloma

June 29th 2015

Evolving Role of Stem Cell Transplant in Multiple Myeloma

June 29th 2015

Frontline Treatments for Multiple Myeloma

June 29th 2015

Treatment Goals in Newly Diagnosed Multiple Myeloma

June 29th 2015

Elotuzumab and Daratumumab in Multiple Myeloma

June 29th 2015

Introduction: Monoclonal Antibodies in Multiple Myeloma

June 29th 2015

Venetoclax Combination Shows Antitumor Activity in Advanced Myeloma

June 20th 2015

A three-drug combination comprising the novel Bcl-2 inhibitor venetoclax, bortezomib, and dexamethasone demonstrated a clinical benefit in heavily pretreated patients with relapsed/refractory multiple myeloma.